Evolution of the Average Target: Pfizer, Inc.

Evolution of the Target Price: Pfizer, Inc.

Changes in Analyst Recommendations: Pfizer, Inc.

ab07d8e941c404c2506c.k-fr6hX5xWZCMES429VPR57m14iC1Psa0643koBaHnA.ybehuyywtxUIUwaNie0Yc_mgv7vNualPjOdO6vQpWj74gaK1TJCyAjR5dA~e40a430f02eadfedbd92552e67ebb4fa
TD Cowen Adjusts Price Target on Pfizer to $30 From $28, Maintains Hold Rating Jul. 15 MT
PFIZER INC : JP Morgan reiterates its Neutral rating Jul. 08 ZD
HSBC Adjusts Price Target on Pfizer to $28 From $26, Maintains Buy Rating Jul. 07 MT
PFIZER INC : UBS remains Neutral Jun. 12 ZD
PFIZER INC : Bernstein reaffirms its Neutral rating Jun. 04 ZD
PFIZER INC : JP Morgan is Neutral Jun. 03 ZD
Berenberg Bank Cuts Pfizer Price Target to $25 From $28, Maintains Hold Rating May. 29 MT
PFIZER INC : Berenberg reaffirms its Neutral rating May. 29 ZD
PFIZER INC : Jefferies remains its Buy rating May. 21 ZD
Jefferies Adjusts Price Target on Pfizer to $33 From $32, Buy Rating Maintained May. 21 MT
HSBC Adjusts Price Target on Pfizer to $26 From $27, Maintains Buy Rating May. 19 MT
Analyst recommendations: Amazon, PepsiCo, Linde, Pfizer, Crowdstrike Holdings... May. 05Zonebourse
Wolfe Research Adjusts Price Target on Pfizer to $23 From $22, Maintains Underperform Rating Apr. 30 MT
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $29, Maintains Neutral Rating Apr. 30 MT
BofA Securities Adjusts Price Target on Pfizer to $27 From $26, Maintains Neutral Rating Apr. 30 MT
UBS Adjusts Price Target on Pfizer to $25 From $24, Maintains Neutral Rating Apr. 30 MT
Leerink Partners Adjusts Price Target on Pfizer to $26 From $28, Maintains Market Perform Rating Apr. 30 MT
Citigroup Adjusts Price Target on Pfizer to $25 From $23, Maintains Neutral Rating Apr. 30 MT
Goldman Sachs Ups Price Target on Pfizer to $27 From $25, Maintains Neutral Rating Apr. 30 MT
Morgan Stanley Lifts Price Target on Pfizer to $32 From $31, Keeps Equalweight Rating Apr. 30 MT
PFIZER INC : Jefferies reaffirms its Buy rating Apr. 29 ZD
PFIZER INC : JP Morgan is Neutral Apr. 29 ZD
PFIZER INC : UBS sticks Neutral Apr. 29 ZD
HSBC Adjusts Price Target on Pfizer to $27 From $35, Maintains Buy Rating Apr. 28 MT
TD Cowen Adjusts Price Target on Pfizer to $28 From $32, Maintains Hold Rating Apr. 22 MT
More recommendations

Consensus (Composite) Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Ecart obj. / dr
+18.92%
+25.05%
+6.82%
+9.28%
+51.9%
+16.99%
- +5.02%
+33.29%
+24.86%
+5.13%
Average +19.73%
Weighted average by Cap. +20.40%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
24.47USD
Average target price
29.23USD
Spread / Average Target
+19.45%
High Price Target
41.49USD
Spread / Highest target
+69.55%
Low Price Target
23.00USD
Spread / Lowest Target
-6.01%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

TD Cowen
HSBC
JPMORGAN Chris Schott
UBS Trung Huynh
BERNSTEIN RESEARCH Justin Smith
Berenberg Bank
BERENBERG Kerry Holford
Jefferies & Co.
JEFFERIES Akash Tewari
Wolfe Research
Redburn Atlantic
BofA Securities
Leerink Partners
Citigroup
Goldman Sachs
Morgan Stanley
BMO Capital
Bernstein
Daiwa Securities
DZ BANK Elmar Kraus
Wells Fargo Securities
Guggenheim
DA Davidson
Argus
Truist Securities
Redburn
JPMorgan Chase
Cantor Fitzgerald
Barclays
SVB Securities LLC
Credit Suisse
Atlantic Equities
Mizuho Securities
Atlantic Securities
SVB Leerink
Independent Research
RBC
RBC Capital Markets
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG MSCI
BBB
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PFE Stock
  4. Consensus Pfizer, Inc.